Novo Nordisk's Wegovy has been approved by the U.S. Food and Drug Administration (FDA), and clinical trial results show that the drug has benefits for heart health.
Novo Nordisk's ADR narrowed its decline to less than 2%.
<img src="https://imageproxy.pbkrs.com/https://wpimg-wscn.awtmt.com/e29dd92b-d0c9-4f24-95ea-8504eecabb0e.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://wpimg-wscn.awtmt.com/e29dd92b-d0c9-4f24-95ea-8504eecabb0e.png"/>

Novo Nordisk's Wegovy has been approved by the U.S. Food and Drug Administration (FDA), and clinical trial results show that the drug has benefits for heart health.

Novo Nordisk AS announced that the clinical trial results of Wegovy show that the drug has benefits for heart health.

Stocks